NL-OMON25484
Other
Not Applicable
Towards a novel immune therapy platform with an innate allogeneic haematopoietic stem cell transplantation in patients with haematological malignancies
MC UtrechtHeidelberglaan 1003584 CX Utrecht0 sites35 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematological malignancies (hematologische maligniteiten)Allogeneic stem cells transplantation (allogene stamcel transplantatie)Innate immune system (aangeboren immuunsysteem)
- Sponsor
- MC UtrechtHeidelberglaan 1003584 CX Utrecht
- Enrollment
- 35
- Status
- Other
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Haematological malignancies eligible to allo\-SCT
Exclusion Criteria
- •Relapse of allo\-SCT within 6 months after allo\-SCT
- •Bilirubin and/or transaminases \> 2\.5 x normal value
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Development of new approaches for immunotherapy of non-small cell lung cancerC34Malignant neoplasm of bronchus and lungDRKS00029641Molekulare PneumologieUniversitätsklinikum Erlangen
Recruiting
Phase 2
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS studyMultiple MyelomaBlood - Haematological diseasesACTRN12621001037897Australasian Myeloma Research Consortium50
Completed
Not Applicable
An immune therapy register for the improvement of drug safety and treatment of patients with Multiple SclerosisG35Multiple sclerosisDRKS00007190Bundesministerium für Bildung und Forschung Dienstsitz Bonn1,886
Not yet recruiting
Not Applicable
To find Natural killers cells as a treatment option for Triple negative breast cancer.Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2023/10/058292Tata Memorial Center
Completed
Not Applicable
Development of a personalized immune-modulating therapy for patients with atopic dermatitis: evaluation of clinical efficacy of autologous immunoglobulin therapy for atopic dermatitis: a randomized, double-blind, placebo-controlled studyDiseases of the skin and subcutaneous tissueKCT0001597Ajou University Hospital51